Literature DB >> 17909013

Prolonged exposure to reduced levels of androgen accelerates prostate cancer progression in Nkx3.1; Pten mutant mice.

Whitney Banach-Petrosky1, Walter J Jessen, Xuesong Ouyang, Hui Gao, Jayashree Rao, John Quinn, Bruce J Aronow, Cory Abate-Shen.   

Abstract

In this report, we have investigated the relationship between androgen levels and prostate tumorigenesis in Nkx3.1; Pten mutant mice, a genetically engineered mouse model of human prostate cancer. By experimentally manipulating serum levels of testosterone in these mice for an extended period (i.e., 7 months), we have found that prolonged exposure of Nkx3.1; Pten mutant mice to androgen levels that are 10-fold lower than normal (the "Low-T" group) resulted in a marked acceleration of prostate tumorigenesis compared with those exposed to androgen levels within the reference range (the "Normal-T" group). We found that prostate tumors from the Low-T mutant mice share a similar gene expression profile as androgen-independent prostate tumors from these mutant mice, which includes the deregulated expression of several genes that are up-regulated in human hormone-refractory prostate cancer, such as Vav3 and Runx1. We propose that exposure to reduced androgens may promote prostate tumorigenesis by selecting for molecular events that promote more aggressive, hormone-refractory tumors.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17909013     DOI: 10.1158/0008-5472.CAN-07-2887

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  40 in total

1.  The steroid receptor coactivator-3 is required for the development of castration-resistant prostate cancer.

Authors:  Jean C-Y Tien; Zhaoliang Liu; Lan Liao; Fen Wang; Yixiang Xu; Ye-Lin Wu; Niya Zhou; Michael Ittmann; Jianming Xu
Journal:  Cancer Res       Date:  2013-05-06       Impact factor: 12.701

Review 2.  Differing levels of testosterone and the prostate: a physiological interplay.

Authors:  S Larry Goldenberg; Anthony Koupparis; Michael E Robinson
Journal:  Nat Rev Urol       Date:  2011-05-31       Impact factor: 14.432

3.  Prostate cancer: towards appropriate use of androgen deprivation therapy.

Authors:  Vahakn B Shahinian
Journal:  Nat Rev Urol       Date:  2013-02-19       Impact factor: 14.432

4.  FGFR1 abrogates inhibitory effect of androgen receptor concurrent with induction of androgen-receptor variants in androgen receptor-negative prostate tumor epithelial cells.

Authors:  Masashi Kobayashi; Yanqing Huang; Chengliu Jin; Yongde Luo; Tetsuji Okamoto; Fen Wang; Wallace L McKeehan
Journal:  Prostate       Date:  2011-03-28       Impact factor: 4.104

5.  Vav3 enhances androgen receptor splice variant activity and is critical for castration-resistant prostate cancer growth and survival.

Authors:  Stephanie O Peacock; Cale D Fahrenholtz; Kerry L Burnstein
Journal:  Mol Endocrinol       Date:  2012-09-28

6.  Persistence of expression of the TMPRSS2:ERG fusion gene after pre-surgery androgen ablation may be associated with early prostate specific antigen relapse of prostate cancer: preliminary results.

Authors:  L Bonaccorsi; G Nesi; F Nuti; M Paglierani; C Krausz; L Masieri; S Serni; L Proietti-Pannunzi; Y Fang; S C Jhanwar; C Orlando; M Carini; G Forti; E Baldi; L Luzzatto
Journal:  J Endocrinol Invest       Date:  2009-05-05       Impact factor: 4.256

7.  Low systemic testosterone levels induce androgen maintenance in benign rat prostate tissue.

Authors:  Ye Zhou; Maya Otto-Duessel; Miaoling He; Susan Markel; Tim Synold; Jeremy O Jones
Journal:  J Mol Endocrinol       Date:  2013-06-29       Impact factor: 5.098

8.  Novel interaction between the co-chaperone Cdc37 and Rho GTPase exchange factor Vav3 promotes androgen receptor activity and prostate cancer growth.

Authors:  Fayi Wu; Stephanie O Peacock; Shuyun Rao; Sandra K Lemmon; Kerry L Burnstein
Journal:  J Biol Chem       Date:  2012-12-31       Impact factor: 5.157

Review 9.  The diverse and contrasting effects of using human prostate cancer cell lines to study androgen receptor roles in prostate cancer.

Authors:  Sheng-Qiang Yu; Kuo-Pao Lai; Shu-Jie Xia; Hong-Chiang Chang; Chawnshang Chang; Shuyuan Yeh
Journal:  Asian J Androl       Date:  2008-12-22       Impact factor: 3.285

10.  A luminal epithelial stem cell that is a cell of origin for prostate cancer.

Authors:  Xi Wang; Marianna Kruithof-de Julio; Kyriakos D Economides; David Walker; Hailong Yu; M Vivienne Halili; Ya-Ping Hu; Sandy M Price; Cory Abate-Shen; Michael M Shen
Journal:  Nature       Date:  2009-09-09       Impact factor: 49.962

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.